Friday 6 November 2026 Export ZOMDF’s income statement to Excel — free account

Zomedica Corp.

ZOMDF Healthcare Medical Devices

Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024.

Revenue: +22.3%
EPS: +48.4%
Free cash flow: +32.5%

Quarter to September 2026, against a year earlier

0.09 0.00 0.00%

Follow ZOMDF

Alert me

Market cap: $95.4M
P/E: 0.0×
Fwd P/E: −1.9×
Dividend yield: —
F-score: 4/9
Altman Z: 0.41
Beneish M: −5.04
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.17

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	6	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.76%

Capital & Financial Ratios $m

Size

Market Cap 95.35

Revenue ttm 38.68

Net income ttm (15.99)

Free cash flow ttm (13.46)

Net debt Q (40.13)

Valuation

P/E 0.00

Forward P/E (1.85)

Price / sales 2.28

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.85

Financial health

Current ratio Q 6.09

Debt / equity Q 0.00

Interest coverage Q 23,073.00

Growth

Revenue growth Q +22.29%

Operating income growth Q +48.15%

EPS, this year −37.14%

EPS, next year A +37.50%

Revenue, next year A +41.52%

EPS, past 5 yrs —

EPS, next 5 yrs A +8.29%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.79%

10-year low 10-year high

P/B against its own 10 years 41.07%

10-year low 10-year high

EV/Sales against its own 10 years 14.46%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	90	71	53	40
Receivables	2	3	3	7
Inventory	5	5	6	6
Other	—	—	—	—
	100	82	64	55

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	—	—	—
Other	0	0	0	0
	9	9	9	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	19.16%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	42.20%	17.71%	(24.43%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY25 Estimate −0.01 Actual −0.02

−0.02 −0.02 −0.02 −0.01 −0.01

Q4 FY24 Met 0.00

Q1 FY25 Miss −0.01

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY24	−0.01	−0.01	Met by 0.00
Q1 FY25	−0.01	−0.02	Miss by 0.01

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.00	0.00	0.00	—	—
’25	(0.07)	(0.01)	(0.01)	0.00	(0.08)
’24	(0.01)	(0.02)	(0.01)	(0.01)	(0.05)
’23	(0.01)	(0.01)	0.00	(0.02)	(0.04)
’22	0.00	(0.01)	(0.01)	0.00	(0.02)
’21	0.00	0.00	(0.01)	0.00	(0.05)
’20	(0.02)	(0.02)	(0.01)	(0.01)	(0.05)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	10	10	—	—
’25	7	7	8	10	32
’24	6	6	7	8	27
’23	5	6	6	7	25
’22	4	4	5	6	19

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	(3)	—	—
’25	(7)	(5)	(5)	(1)	(18)
’24	(8)	(7)	(5)	(5)	(24)
’23	(4)	(4)	(3)	(5)	(16)
’22	(2)	(4)	(3)	(2)	(12)
’21	(3)	(2)	(5)	(5)	(14)
’20	(2)	(6)	(6)	(3)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	(3)	—	—
’25	(7)	(6)	(5)	(1)	(19)
’24	(10)	(8)	(6)	(7)	(30)
’23	(9)	(6)	(10)	(7)	(31)
’22	(3)	(4)	(4)	(3)	(14)
’21	(3)	(2)	(5)	(5)	(15)
’20	(2)	(6)	(6)	(3)	(16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	4	19	25	27	32	39		+66.8%	45	59	—	+35.2%
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	73.89	71.15	68.76	69.95	67.68	63.96		+67.7 pt	Powerpack Zomedica Corp.’s next three years, line by line Analysts expect revenue to grow 35.2% a year to 2028 — slower than the 66.8% of the last 4 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(6)	(8)	(17)	(20)	(17)	(21)	(19)	(36)	(48)	(82)	(16)		+34.4%
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(501.26)	(102.38)	(142.38)	(174.23)	(256.43)	(41.71)		(256.4) pt
	Net income	(6)	(8)	(166)	(20)	(17)	(18)	(17)	(35)	(47)	(82)	(16)		+34.3%
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03	0.03	0.03	0.04		n/m
	Earnings	(0.07)	(0.09)	(0.18)	(0.19)	(0.05)	(0.05)	(0.02)	(0.04)	(0.05)	(0.08)	(0.02)		+1.2%
	Cash flow	(0.06)	(0.08)	(1.19)	(0.15)	(0.04)	(0.01)	(0.01)	(0.02)	(0.02)	(0.02)	(0.01)		(12.0%)
	Capex	0.00	0.00	(0.07)	(0.01)	0.00	0.00	0.00	(0.02)	(0.01)	0.00	0.00		(11.5%)
	Free cash flow	(0.06)	(0.08)	(1.26)	(0.15)	(0.04)	(0.02)	(0.01)	(0.03)	(0.03)	(0.02)	(0.01)		(12.0%)
	Book value	0.05	0.05	0.04	0.02	0.14	0.28	0.27	0.24	0.20	0.12	0.11		+10.5%
	Shares, m	80	87	93	106	364	957	980	980	980	980	980		+32.1%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	71.75	8.28	7.39	4.31	3.06	2.28		19.0
	P/B	—	—	—	—	—	1.09	0.59	0.78	0.60	0.85	0.85		0.8
	EV/Sales	—	—	—	—	—	24.70	2.23	3.82	1.71	1.41	1.26		6.8
	EV/FCF	—	—	—	—	—	(6.90)	(2.89)	(3.06)	(1.54)	(2.43)	(3.61)		(3.4)
Cash, $m
Cash, $m	Operating cash flow	(5)	(7)	(111)	(16)	(16)	(14)	(12)	(16)	(24)	(18)	(11)		+16.2%
	Capex	0	0	(6)	(1)	0	(1)	(3)	(15)	(7)	(1)	(2)		+16.4%
	Free cash flow	(5)	(7)	(118)	(16)	(16)	(15)	(14)	(31)	(30)	(19)	(13)		+16.2%
Balance, $m
Balance, $m	Working capital	3	3	1	0	62	196	116	91	72	55	46		+38.9%
	Net debt	(3)	(3)	(2)	(1)	(61)	(195)	(115)	(90)	(71)	(53)	(40)		+36.5%
	Shareholders’ equity	4	4	4	2	51	271	267	240	196	115	104		+46.0%
Returns, %
Returns, %	ROA	(141.12)	(164.74)	(295.98)	(387.30)	(48.09)	(29.10)	(6.08)	(12.96)	(20.40)	(48.96)	(13.01)		+92.2 pt
	ROIC	(588.92)	(538.08)	(603.60)	(780.19)	0.00	(17.59)	(9.00)	(18.09)	(25.67)	(84.84)	(17.12)		+504.1 pt
	ROE	(158.39)	(196.20)	(413.91)	637.28	(82.10)	(31.32)	(6.32)	(13.61)	(21.57)	(52.63)	(14.28)		+105.8 pt
People
People	Employees	20	20	27	28	19	47	85	144	152	141	—		+24.2%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.09	0.22	0.17	0.18	0.23	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$128.9M	— (loss-making)	— (loss-making)	+8.95% (above 0%: growing)	n/m	+53.17% (above 0%: growing)	64.16%	(4.07%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+22.29% (above 0%: growing)	n/m	+32.51% (above 0%: growing)	61.06%	(34.60%)
CATX Perspective Therapeutics, Inc.	$90.0M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
NYXH Nyxoah SA	$82.6M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
SERA Sera Prognostics, Inc.	$82.1M	— (loss-making)	— (loss-making)	+162.50% (above 0%: growing)	n/m	−12.79% (below 0%: shrinking)	0.00%	(21,159.52%)	Compare
LUCD Lucid Diagnostics Inc.	$79.3M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
OM Outset Medical, Inc.	$77.0M	— (loss-making)	— (loss-making)	+14.15% (above 0%: growing)	n/m	−61.85% (below 0%: shrinking)	40.69%	(36.52%)	Compare
HYPR Hyperfine, Inc.	$72.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
MBOT Microbot Medical Inc.	$71.9M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
Median of peers	$80.7M	—	—	+35.78%	—	−9.92%	45.70%	(568.35%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 6.75%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Zomedica Corp. (ZOMDF) Latest News

4 Nov

Impact 4 · 4:17 PM · ACCESS Newswire

Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth

Impact 3 · 4:15 PM · ACCESS Newswire

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

8 Oct

Impact 3 · 6:00 AM · ACCESS Newswire

Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption

22 Sep

Impact 4 · 6:00 AM · ACCESS Newswire

Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices

13 Aug

Impact 4 · 6:00 AM

Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

5 Aug

Impact 4 · 4:15 PM

Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

14 May

Impact 3 · 6:00 AM · ACCESS Newswire

Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market

6 May

Impact 4 · 5:05 PM · ACCESS Newswire

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity

18 Mar

Impact 4 · 6:00 AM · ACCESS Newswire

Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

16 Mar

Impact 4 · 4:30 PM · ACCESS Newswire

Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity

25 Feb

Impact 4 · 6:30 AM

Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology

5 Feb

Impact 3 · 6:30 AM · ACCESS Newswire

Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline

23 Jan

Impact 4 · 4:01 PM · ACCESS Newswire

Zomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity

22 Jan

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health

14 Jan

Impact 3 · 6:30 AM · ACCESS Newswire

Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth

30 Dec

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary Market

11 Dec

Impact 3 · 6:30 AM · ACCESS NewswireSimply Wall St.GuruFocus.com24/7 Wall St.Simply Wall St.MT NewswiresInsider MonkeyMT Newswires

Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv

4 Dec

Impact 3 · 6:30 AM

Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay

11 Nov

Impact 3 · 6:30 AM · ACCESS Newswire

Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review

6 Nov

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential

23 Oct

Impact 4 · 6:30 AM · ACCESS NewswireInsider MonkeySimply Wall St.ZacksBarchartInsider MonkeyMT NewswiresMT Newswires

Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets

14 Oct

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union

9 Oct

Impact 3 · 6:30 AM · ACCESS Newswire

Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar

23 Sep

Impact 3 · 6:30 AM · ACCESS Newswire

Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay

18 Sep

Impact 4 · 6:30 AM

Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents

12 Sep

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging

10 Sep

Impact 3 · 6:30 AM

Zomedica and UXR Announce Expanded Distribution Agreement in Canada

3 Sep

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio

19 Aug

Impact 4 · 6:30 AM · ACCESS Newswire

Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

12 Aug

Impact 4 · 6:30 AM

Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Zomedica Corp. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Zomedica Corp. (ZOMDF) Latest News

4 Nov

8 Oct

22 Sep

13 Aug

5 Aug

14 May

6 May

18 Mar

16 Mar

25 Feb

5 Feb

23 Jan

22 Jan

14 Jan

30 Dec

11 Dec

4 Dec

11 Nov

6 Nov

23 Oct

14 Oct

9 Oct

23 Sep

18 Sep

12 Sep

10 Sep

3 Sep

19 Aug

12 Aug

Stockrow Weekly